Capsicum / Cayenne

Metadata

Approved Indications

German Commission E (Positive Monograph)

• Painful muscle tension (spasm) in the shoulder, arm, and spine region
• Approved for adults and schoolchildren (one of the few herbs with pediatric mention)

ESCOP

• Muscle pain (e.g., back pain)
• Pain in degenerative joint diseases (osteoarthritis)
• Rheumatoid arthritis pain
• Nerve pain (e.g., post-herpetic neuralgia, painful diabetic neuropathy)
• Itching of various causes (e.g., psoriasis, dialysis-related pruritus)

EMA/HMPC

• Well-established use: Relief of muscle pain, such as low back pain (adults >=18 years)
  • Duration: Not continuously for more than 3 weeks; after 3 weeks, a break of at least 2 weeks required
• Traditional use: Not separately designated (well-established use covers the primary indication)

Agreement/Disagreement Among Authorities

• Strong agreement: All authorities recognize topical muscle/joint pain as the primary indication
• ESCOP is broadest: Includes neuropathic pain (post-herpetic neuralgia, diabetic neuropathy), rheumatoid arthritis, and pruritus — reflecting the expanded evidence base
• Commission E is narrowest: Limits to muscle tension in shoulder/arm/spine, but notably includes schoolchildren
• EMA specifies duration limits: 3 weeks maximum continuous use with 2-week break — a practical clinical guideline
• Neuropathic pain: ESCOP recognizes this; Commission E does not explicitly; EMA’s well-established use is specifically for muscle pain

Conditions Treated

Primary (Well-Established Evidence)

• Musculoskeletal pain (back pain, shoulder/neck tension) — strongest regulatory support
• Osteoarthritis pain — meta-analytic evidence
• Post-herpetic neuralgia — strong evidence; basis for prescription 8% patch (Qutenza)
• Painful diabetic neuropathy — moderate-strong evidence

Secondary (Supported by Clinical Evidence)

• Rheumatoid arthritis pain (adjunctive topical therapy)
• Post-surgical neuropathic pain
• Complex regional pain syndrome
• Psoriatic pruritus
• Cluster headache (intranasal application — specialized use)

Mechanism of Action

Key Active Compound

• Capsaicin (8-methyl-N-vanillyl-6-nonenamide) — the principal capsaicinoid; responsible for the “hot” sensation and virtually all therapeutic activity
• Dihydrocapsaicin — secondary capsaicinoid
• Capsaicinoid content in dried fruit: 0.1-1.5% (varies by cultivar)

Pharmacological Mechanism: TRPV1-Mediated Defunctionalization

The mechanism of capsaicin has been REVISED from the older “substance P depletion” model. The current understanding is:

Step 1: TRPV1 Receptor Activation

• Capsaicin is a highly selective agonist of the TRPV1 (transient receptor potential vanilloid 1) receptor
• TRPV1 is expressed on C-fiber and A-delta nociceptive neurons
• Activation causes initial depolarization: sensation of burning, stinging, erythema

Step 2: Nociceptor Defunctionalization (NOT Simple Substance P Depletion)

The prolonged or high-concentration exposure to capsaicin causes a cascade of effects collectively termed defunctionalization:

1. Loss of membrane potential: Sustained TRPV1 activation leads to persistent depolarization and eventual electrical silencing
2. Reversible retraction of nerve terminals: Epidermal and dermal nerve fiber endings retract from the skin surface
3. Impaired neurotrophic factor transport: Loss of axonal transport of nerve growth factor (NGF) and other trophic factors
4. Altered neuronal phenotype: Changes in neuropeptide expression and receptor density
5. Substance P depletion: This occurs but is now understood to be a consequence, not the primary mechanism

Step 3: Recovery

• Defunctionalization is REVERSIBLE over weeks to months after cessation of capsaicin exposure
• Nerve terminal re-innervation occurs, restoring normal sensation
• This is why intermittent use (3 weeks on, 2 weeks off) is recommended for low-concentration formulations

Clinical Implication of Updated Mechanism

The defunctionalization model explains why:

• Initial application causes burning (TRPV1 activation)
• Burning diminishes with repeated application (desensitization/defunctionalization)
• Pain relief persists beyond the acute application period
• Recovery occurs after discontinuation

Comparison: Low-Concentration vs. High-Concentration

Clinical Evidence Summary

Systematic Reviews and Meta-Analyses

• Mason et al. (2004): Cochrane review of low-concentration capsaicin for musculoskeletal and neuropathic pain; found modest efficacy with NNT of 8.1 for musculoskeletal pain
• Deal et al. (1991): RCT of 0.025% capsaicin in 70 OA patients and 31 RA patients; significant benefit vs. placebo
• Multiple meta-analyses confirm safety and modest efficacy of low-concentration formulations for OA

Key Individual Trials

Osteoarthritis

Low Back Pain (Plaster/Patch)

Neuropathic Pain (Higher Concentrations)

• Post-herpetic neuralgia: 0.075% cream showed statistically significant benefit in multiple trials
• 8% patch (Qutenza): Single 60-minute application provides up to 12 weeks of pain relief; FDA-approved for PHN and diabetic neuropathy; EMA-approved

Effect Sizes

• OA: Modest but significant; NNT ~8 for musculoskeletal pain (low-concentration)
• PHN: More robust; 8% patch shows 30% pain reduction in ~40% of patients
• Low back pain: Significant improvement vs. placebo with plaster formulations

Limitations

• Low-concentration formulations require 3-4x daily application, which reduces compliance
• Initial burning sensation leads to dropout in some patients
• Blinding is difficult (active treatment causes obvious burning)
• Effect sizes for OA are modest compared to oral anti-inflammatories

European vs. US/Anglophone Consensus

Unique position: Capsaicin/capsicum is the MOST mainstream of the herbs in this module, recognized by both European and US clinicians. The 8% patch (Qutenza) bridges the gap between phytotherapy and conventional pharmacology — it is literally a plant-derived active ingredient in a prescription drug format.

Safety Profile

Contraindications

• Broken, damaged, or irritated skin: Never apply to cuts, wounds, rashes, dermatitis, or sunburned skin
• Mucous membranes: Avoid contact with eyes, nose, mouth, genitals
• Known capsaicin allergy (rare)
• Asthma: Greater sensitivity to capsaicin; risk of bronchospasm, especially with high-concentration or heated preparations
• Children under 18: EMA restriction for well-established use formulations (Commission E allows use in schoolchildren for plasters)

Drug Interactions

• ACE inhibitors: Capsaicin may enhance cough associated with ACE inhibitors (TRPV1 is expressed in airway neurons)
• Anticoagulants: Theoretical interaction if significant systemic absorption (unlikely with topical use on intact skin)
• Antihypertensives: Possible additive hypotensive effect (marginal)
• Other topical analgesics: Avoid concurrent application to same area (additive irritation)
• Generally minimal drug interactions with topical use

Side Effects

• Expected: Burning, stinging, erythema at application site (TRPV1 activation; diminishes with repeated use)
• Common: Local warmth, itching
• Uncommon: Blistering (with prolonged application or sensitive skin)
• Practical issue: Inadvertent transfer to eyes, mucous membranes (wash hands thoroughly after application; consider gloves)
• With 8% patch: Severe localized pain during application (requires pre-treatment with topical anesthetic); transient hypertension

Pregnancy and Lactation

• Pregnancy: Insufficient data for topical use; dietary capsaicin consumption appears safe. Topical medicinal use: use only if clearly needed
• Lactation: Capsaicin may enter breast milk; avoid application on chest/breast area; dietary use appears safe

Clinical Dosage

Recommended Forms and Doses

Key Dosing Principles

1. Start low: Begin with 0.025% for capsaicin-naive patients; increase to 0.075% if tolerated
2. Duration limits (EMA): Maximum 3 weeks continuous use for low-concentration products; then 2-week break
3. Warn about burning: Inform patients that initial burning is EXPECTED and diminishes with continued use over 3-7 days
4. Application technique: Apply thin film; rub gently; wash hands immediately (or use gloves)
5. Do NOT apply heat: Heating pads, hot baths after application intensify burning dangerously
6. NOT on broken skin: Only intact skin
7. Compliance: The 3-4x daily application requirement is a major compliance barrier; plasters/patches offer better adherence

Key Products

• Capsaicin cream (generic OTC): 0.025%, 0.075%, 0.1% — multiple brands
• Qutenza (Grünenthal/Averitas): 8% capsaicin patch — prescription neuropathic pain treatment
• ABC Waerme-Pflaster (Germany): Capsicum plaster; widely used in German pharmacy practice
• Salonpas Hot (US/international): Capsaicin-containing patch
• Zostrix (US): Brand-name 0.025% and 0.075% capsaicin cream
• Capzasin (US): Various capsaicin topical products

Sources

• EMA/HMPC. European Union herbal monograph on Capsicum annuum L. var. minimum (Miller) Heiser and small fruited varieties of Capsicum frutescens L., fructus. EMA/HMPC/674381/2013.
• EMA/HMPC. Assessment report on Capsicum annuum L. var. minimum. Final.
• Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011;107(4):490-502.
• Deal CL et al. Treatment of arthritis with topical capsaicin: a double-blind trial. Clin Ther. 1991;13(3):383-395.
• Mason L et al. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ. 2004;328(7446):991.
• ESCOP. Capsici fructus acer Monograph.
• German Commission E. Capsicum Monograph.
• Capsaicin. StatPearls. NCBI Bookshelf.

Connections

• Compare with Arnica and Comfrey — alternative topical approaches with different mechanisms
• Compare with Willow Bark — oral vs. topical approach to musculoskeletal pain
• The 8% patch (Qutenza) represents the most “pharmaceutical” end of the herbal medicine spectrum